Education
About Us
Working with TipRanks
Follow Us
NVOH - ETF AI Analysis
Top Page
Novo Nordisk A/S (B Shares) ADRhedged (NVOH)
Rating:71Outperform
Price Target:
$34.00
Positive Factors
Low Expense Ratio
The ETF has a very low expense ratio, making it cost-effective for investors.
Focused Sector Exposure
The ETF’s heavy focus on the health care sector provides targeted exposure to a defensive industry.
Large Assets Under Management
The fund has significant assets under management, indicating strong investor interest and stability.
Negative Factors
Over-Concentration in One Stock
Nearly all of the ETF’s portfolio is invested in a single company, increasing risk from poor performance in that stock.
Weak Recent Performance
The ETF has shown negative returns across multiple timeframes, which may concern investors seeking growth.
Limited Geographic Diversification
The ETF is heavily concentrated in U.S. companies, offering little exposure to international markets.
NVOH vs. SPDR S&P 500 ETF (SPY)
AUM2.32M
RegionEurope
Expense Ratio0.19%
Beta1.13
IssuerADRhedged
Inception DateJan 07, 2025
Dividend Yield0.58%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,228
30 Day Avg. Volume4,253
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
32.92Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
NVOH Summary
The NVOH ETF focuses on the Health Care sector, specifically pharmaceuticals, and provides exposure to Novo Nordisk, a global leader in diabetes care and obesity treatment. This ETF is designed to reduce currency risk for U.S. investors, making it a more stable option for those interested in international healthcare companies. Novo Nordisk is a well-known company driving innovation in chronic disease treatments, and investing in this ETF could be appealing for those seeking growth in the healthcare industry. However, new investors should note that this ETF is heavily reliant on the performance of Novo Nordisk, which means its value can fluctuate based on the company’s success.
How much will it cost me?The NVOH ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed funds, as it focuses on a specific company and niche within the healthcare sector, keeping costs relatively modest.
What would affect this ETF?The NVOH ETF could benefit from the growing global demand for innovative healthcare solutions, particularly in diabetes and obesity treatments, areas where Novo Nordisk is a leader. However, potential risks include regulatory changes in the pharmaceutical industry or shifts in healthcare policies that could impact drug pricing and market access. Additionally, while the fund mitigates currency risk, broader economic challenges in Europe or Denmark could still influence its performance.
NVOH Top 10 Holdings
The NVOH ETF is heavily concentrated in Novo Nordisk, which makes up nearly the entire fund and anchors its performance. While Novo Nordisk has been a global leader in diabetes and obesity treatments, its stock has been losing momentum recently, with mixed signals from U.S. market challenges and slowing cash flow growth. This singular focus on the pharmaceutical sector, particularly in Denmark, means the fund’s fortunes are tightly tied to Novo Nordisk’s ability to overcome these hurdles and regain its stride. Investors should weigh the risks of this concentrated exposure against the company’s long-term potential.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 96.81% | $2.20M | $229.37B | -53.52% | 73 Outperform |
NVOH Technical Analysis
Negative
―
Price Trends
30.70
Negative
32.68
Negative
37.54
Negative
Market Momentum
-0.61
Positive
34.47
Neutral
20.80
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 30.81, equal to the 50-day MA of 30.70, and equal to the 200-day MA of 37.54, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 34.47 is Neutral, neither overbought nor oversold. The STOCH value of 20.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVOH.
NVOH Peer Comparison
Comparison Results
Performance Comparison
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
28.46
-22.00
-43.60%
CANC
Tema Oncology ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
ARMH
Arm Holdings PLC ADRhedged
―
―
―
STHH
STMicroelectronics NV ADRhedged
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents